Form 4: Bolt Biotherapeutics CEO Acquires 440,000 Stock Options
SEC Form 4 Filing
William P. Quinn, President, CEO, and CFO of Bolt Biotherapeutics, acquired 440,000 stock options on July 23, 2024.
Summary
- William P. Quinn, the President, CEO, and CFO of Bolt Biotherapeutics, filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on July 23, 2024, where Quinn acquired 440,000 stock options.
- The exercise price of these options is $0.7301.
- The options vest monthly over three years, starting July 15, 2024, provided Quinn continuously provides services to the Issuer.
- The options expire on July 22, 2034.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are routine and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.
Stakeholder Impact
- The stock option grant aligns the CEO's interests with those of the shareholders, incentivizing him to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 07/15/2024 | Start date for monthly vesting of stock options. |
| 07/23/2024 | Date of transaction: CEO acquired 440,000 stock options. |
| 07/22/2034 | Expiration date of the stock options. |
| 07/24/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.